Shares of Imperva Inc (NYSE:IMPV) have earned an average recommendation of “Buy” from the twenty-two research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $52.83.

IMPV has been the subject of a number of recent research reports. Evercore ISI set a $56.00 price objective on Imperva and gave the company a “buy” rating in a research note on Thursday, August 10th. BidaskClub lowered Imperva from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Monness Crespi & Hardt lifted their price objective on Imperva from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Piper Jaffray Companies set a $58.00 price objective on Imperva and gave the company a “buy” rating in a research note on Monday, August 28th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $47.00 price objective on shares of Imperva in a research note on Friday, July 14th.

TRADEMARK VIOLATION WARNING: “Imperva Inc (IMPV) Receives $52.83 Consensus Target Price from Analysts” was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at http://www.mareainformativa.com/imperva-inc-impv-receives-52-83-consensus-target-price-from-analysts/117977/.

Imperva (IMPV) traded up 1.26% during mid-day trading on Friday, reaching $44.30. The company’s stock had a trading volume of 648,791 shares. The stock has a 50-day moving average price of $44.11 and a 200-day moving average price of $45.69. Imperva has a one year low of $34.40 and a one year high of $57.24. The company’s market capitalization is $1.50 billion.

Imperva (NYSE:IMPV) last released its quarterly earnings data on Thursday, July 27th. The software maker reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.15). The company had revenue of $74.44 million for the quarter, compared to analysts’ expectations of $74.30 million. Imperva had a negative net margin of 4.69% and a negative return on equity of 5.00%. The business’s quarterly revenue was up 28.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.23) EPS. Equities research analysts forecast that Imperva will post $0.81 EPS for the current year.

In related news, Director Anthony J. Bettencourt sold 99,598 shares of Imperva stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $43.59, for a total value of $4,341,476.82. Following the sale, the director now directly owns 99,598 shares in the company, valued at approximately $4,341,476.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Stephens Investment Management Group LLC boosted its holdings in shares of Imperva by 1.7% during the 1st quarter. Stephens Investment Management Group LLC now owns 228,024 shares of the software maker’s stock worth $9,360,000 after purchasing an additional 3,894 shares during the last quarter. Capital Fund Management S.A. boosted its holdings in shares of Imperva by 85.6% during the 2nd quarter. Capital Fund Management S.A. now owns 113,951 shares of the software maker’s stock worth $5,453,000 after purchasing an additional 52,559 shares during the last quarter. Bank of Nova Scotia acquired a new position in shares of Imperva during the 1st quarter worth approximately $7,184,000. Eagle Asset Management Inc. boosted its holdings in shares of Imperva by 17.7% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,279,848 shares of the software maker’s stock worth $61,240,000 after purchasing an additional 192,625 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC boosted its holdings in shares of Imperva by 127.3% during the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 25,000 shares of the software maker’s stock worth $1,026,000 after purchasing an additional 14,000 shares during the last quarter. Institutional investors own 92.72% of the company’s stock.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Analyst Recommendations for Imperva (NYSE:IMPV)

Receive News & Stock Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related stocks with our FREE daily email newsletter.